Paracetamol (acetaminophen) protein adduct concentrations during therapeutic dosing.

ABSTRACT:

Background

Paracetamol protein adducts (PPA) are a biomarker of paracetamol exposure. PPA are quantified as paracetamol-cysteine (APAP-CYS), and concentrations above 1.1 μmol l(-1) have been suggested as a marker of paracetamol-induced hepatotoxicity. However, there is little information on the range of concentrations observed during prolonged therapeutic dosing.

Aim

The aim of the present study was to describe the concentration of PPA in the serum of subjects taking therapeutic doses of paracetamol for at least 16 days.

Methods

Preplanned secondary aim of a prospective randomized controlled (placebo vs. 4g day(-1) paracetamol) trial. We measured subjects' serum PPA concentrations every 3 days for a minimum of 16 days. We also measured concentrations on study days 1-3

SUBMITTER: Heard K 

PROVIDER: S-EPMC4767203 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature